Susan Foden

Excalibur Fund Managers Ltd (Excalibur) is a venture capital firm founded in 1996 by Christopher Evans. The firm is headquartered in London, United Kingdom.

Cancer Research Technology Ltd. develops cancer therapeutics, vaccines, and diagnostics. The firm also provides project development, commercialization, drug discovery, clinical development, imaging, and funding services. The company was founded in 2002 and is headquartered in London, the United Kingdom.

Innovata Ltd. researches and develops pharmaceutical and medical products. It develops pulmonary products for the treatment of respiratory disorders and other serious diseases. The company was founded on July 20,1987 and is headquartered in Nottingham, the United Kingdom.

Lifearc provides research services. It specializes in intellectual property management, drug discovery, medical diagnostics and antibody engineering. The firm services include complete technology transfer service for scientists in MRC units and institutes, Awards to Inventors, Collaborative drug discovery and antibody engineering, Funding early stage research with commercial/translational potential and protecting new ideas. The company is headquartered in London, the United Kingdom.

The UK Innovation & Science Seed Fund LP, an evergreen fund, invests in seed-stage companies located in the United Kingdom. It targets companies operating in biotechnology, synthetic biology, engineering, agriculture, computer science, and environmental technology sectors. It provides equity financing for seed to early-stage transactions.

Cizzle Biotechnology Ltd. develops therapeutic products for lung cancer. The firm promotes DNA replication and is involved in its organization and control. The company was founded by Dawn Coverley and Justin Ainscough in 2005 and is headquartered in York, the United Kingdom.

Celltech Ltd. provides research and development on natural science and engineering. The company was founded in 1999 and is headquartered in Slough, GB.

Evgen Ltd. develops novel glucosinolate based products for the prevention and treatment of human disease. It engages in the clinical stage drug development that lead programmes are in breast cancer and subarachnoid haemorrhage, a type of stroke. Its activities also include carrying out preclinical work in multiple sclerosis and has a clinical interest in prostate cancer. The firm holds proprietary technology that enables sulforaphane to be synthesized and then subsequently stabilized for pharmaceutical application. The company was founded by Dr. Stephen Franklin on October 18, 2007 and is headquartered in Liverpool, the United Kingdom.

Part of UCB SA, Celltech Group Ltd. is an investment holding British company. The company is based in Slough, UK. Celltech Group was founded in 1987.

Oxford Ancestors Ltd. provides portal engine and content management system. It offers maternal and paternal ancestry, genealogy services and database zone products. The company was founded by Bryan Clifford Sykes in 2000 and is headquartered in Bicester, the United Kingdom.

Neurocentrx Pharma Ltd. is a British pharmaceutical company that manufactures and distributes medicines. The company is based in Edinburgh, UK. Neurocentrx Pharma was founded by Howard Marriage, Ronald M. Lindsay, and Carmel Reilly. Carmel Reilly has been the CEO since incorporation.

Butterfly Conservation is a British charity that aims to save butterflies, moths, and their habitats. Butterfly Conservation has more than 40,000 members in the UK and 32 volunteer-run branches throughout the British Isles. The non-profit company is based in Wareham, UK. The organization operates 36 nature reserves and is leading or involved in 73 landscape-scale projects to conserve habitats. The organization employs over 80 people, including many highly qualified scientists, making it the world's largest research institute for butterflies and moths. Butterfly Conservation's new strategy sets out three key goals to drive forward their work, making a pledge for the impact they will make on threatened species, doubling their impact on landscape restoration, and involving people in transforming spaces for butterflies and moths. The British company was founded in 1968, and Julie Williams has been the CEO of the company since 2000.

Cascade Ltd. is a Belarusian company that produces a variety of non-alcoholic beverages, including carbonated soft drinks, flavored water, and mineral water. Cascade is based in Borisov, BY and offers job opportunities. The private company's products come in various sizes, ranging from 0.5 liters to 2.0 liters. The company emphasizes the health benefits of its products and encourages customers to maintain their body's water balance throughout the day.

Cell Therapy Catapult Ltd. engages in the development, delivery, and commercializing of cell and gene therapy. The company was founded in 2012 and is headquartered in London, the United Kingdom.

Part of Philip Morris International, Inc., Vectura Ltd. is a leading inhalation CDMO that provides innovative inhaled drug development solutions to help bring medicines to market. The company is based in Chippenham, UK, and has planning permission for a new 10,000-square meter facility on Bristol & Bath Science Park - inhalation center of excellence. Vectura is reimagining healthcare and self-care, transforming the lives of airways disease patients. Founded in 1983, the British company specializes in formulation science, device technology, and inhaled development expertise to bring DPI, PMDI, and nebulizer medicines to market.

Elara Pharmaceuticals GmbH focuses on the development of novel treatments for malignant diseases. It has developed three distinct and proprietary dual mechanism chemotypes that potently inhibit the HIF signaling pathway and induce apoptosis. The firm has identified compounds with excellent in vitro activity against a diverse set of tumor cell lines and superior pharmacokinetic and toxicity profiles in vivo. The company was founded by Frank Gannon, Joe D. Lewis and George Reid on July 27, 2006 and is headquartered in Heidelberg, Germany.

Vectura GmbH manufactures and develops pharmaceutical therapies for airways diseases. It offers dry powder formulation technology, device technology, and development capabilities. The company was founded by Gerhard Scheuch in 1997 and is headquartered in Gemünden, Germany.